Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAd5
- Development stage
- Preclinical
- Lead developer
- ImmunityBio
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular
01
Overview
HAd5 is an adenovirus-based vaccine candidate developed by ImmunityBio, primarily for the prevention and treatment of COVID-19. It was a key component of a joint collaboration between ImmunityBio and its affiliate NantKwest, aiming to combine various immunotherapies for a comprehensive approach against the virus. The vaccine is also being developed for oral delivery through a licensing agreement with iosBio, utilizing their OraPro thermal stabilization platform to create a room-temperature-stable oral capsule, thereby simplifying distribution by eliminating cold-chain requirements.
- Other names
- ImmunityBio COVID-19 vaccinebivalent hAd5 vaccine - ImmunityBiohAd5 T-Cell COVID-19 VaccinehAd-5 T-Cell COVID-19 VaccinehAd 5 T-Cell COVID-19 VaccineSARS-CoV-2 infections vaccine - ImmunityBioSARS-CoV2 infections vaccine - ImmunityBioSARS-CoV 2 infections vaccine - ImmunityBio
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)
Beyond the preview
Go deeper on HAd5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAd5.